Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
RLMD
RLMD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RLMD News
Xenon and Relmada Surge on Positive Drug Data
13h ago
Yahoo Finance
Relmada Therapeutics to Participate in Healthcare Conference
16h ago
Newsfilter
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
21h ago
Benzinga
Relmada Therapeutics Reports Promising Interim Data for Bladder Cancer Treatment
23h ago
Benzinga
Relmada's Bladder Cancer Treatment Shows Promising Phase 2 Trial Results
1d ago
stocktwits
Relmada Secures $160 Million in PIPE Financing
1d ago
Newsfilter
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
Feb 26 2026
PRnewswire
Helus Pharma Achieves Breakthrough in Depression Treatment
Feb 26 2026
Newsfilter
BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target
Dec 22 2025
Benzinga
Relmada Therapeutics Sets Price for $100 Million Underwritten Common Stock and Pre-Funded Warrant Offering
Nov 04 2025
Newsfilter
Relmada Receives FDA Feedback Endorsing Two Distinct Acceptable Pathways for NDV-01 Registration Studies in Non-Muscle Invasive Bladder Cancer
Nov 04 2025
Newsfilter
Relmada Therapeutics Welcomes Renowned Urologic Oncologist Max Kates, MD, to Clinical Advisory Board for NDV-01 Development
Oct 07 2025
Newsfilter
Insider Buying Update for Tuesday, September 2: RLMD, STRA
Sep 02 2025
NASDAQ.COM
Relmada outlines 2026 trial launches for NDV-01 and sepranolone as pipeline advances
Aug 08 2025
SeekingAlpha
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Jul 22 2025
Benzinga
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Jul 15 2025
Newsfilter
Show More News
